Loading data for FLNA — first visit, this takes a few seconds.
Filana Therapeutics, Inc. (FLNA)
NasdaqCM: FLNA
· Real-Time Price · USD
0.95
+0.02 (2.15%)
At close: Sep 01, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Filana Therapeutics, Inc. (FLNA) Stock Price, Analysis & Data
No data available
| Bid | 1.02 |
| Market Cap | 41.4M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.3M |
| -0.69 | |
| -0.87 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.65 |
| P/S (ttm) | 0.00 |
| Earnings Date | Oct 29, 2026 |
| Ask | 0.98 |
| Volume | 70,158 |
| Avg. Volume (20D) | 352,184 |
| Open | 0.92 |
| Previous Close | 0.93 |
| Day's Range | 0.91 - 0.95 |
| 52-Week Range | 0.85 - 4.98 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | Dec 13, 2012 |
About FLNA
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2000
Employees 17
Stock Exchange NasdaqCM
Ticker Symbol FLNA
Website https://www.filanatx.com
Financial Performance
In 2025, Filana Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -90.97M, an increase of 273.73%.
Financial StatementsEarnings Surprise
Filana Therapeutics has released their quarterly earnings on Jul 29, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.18 exceeds estimates by 0.04, with 68.42% YoY growth.
Filana Therapeutics, Inc. is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
